Sage Therapeutics: Q2 Earnings Insights

 

Shares of Sage Therapeutics SAGE moved higher by 11.9% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 12.02% over the past year to ($1.83), which missed the estimate of ($1.69).

Revenue of $1,643,000 up by 50.87% year over year, which missed the estimate of $2,010,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 03, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/oih2pf9o

Technicals

Company's 52-week high was at $98.39

52-week low: $42.85

Price action over last quarter: down 31.43%

Company Overview

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!